GBI Research, a leading business intelligence provider, has released its latest research report, "Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth". The asthma market is forecast to grow marginally over the forecast period across the leading eight developed nations, from $16.6 billion in 2012 to a projected value of $21.6 billion in 2019.
The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence.
The global injectable drug delivery technologies market was valued at $22.5 billion in 2012, and is expected to reach $43.3 billion by 2017 at a CAGR of 14.0% from 2012 to 2017. Injectable drug delivery technologies are the combination of two major segments; devices and formulations.
The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. See Full Report: http://goo.gl/6R29xF
Increasing allergic rhinitis is a major factor for allergic asthma leading to increase in research for the development of allergic immunotherapies for the treatment of asthma.
Asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape.
GBI Research, a leading business intelligence provider, has released its latest research report, Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations. The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. Enquiry @ http://www.researchbeam.com/asthma-therapeutics-in-major-developed-to-2020-personalized-treatment-for-severe-asthma-to-drive-growth-despite-patent-expirations-market/enquire-about-report
Asthma Therapeutics Market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%.
Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations is significant. GBI Research analysis identified 59 first-in-class programs in the asthma pipeline, acting on 43 first-in-class molecular targets, accounting for 23% of all products with a disclosed molecular target and reflective of the high degree of innovation in this indication. Enquiry @ http://www.researchbeam.com/frontier-pharma-asthma-identifying-and-commercializing-first-in-class-innovation-market/enquire-about-report
"Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns", which provides in-depth analysis of epilepsy market within the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada.
During the forecast period from 2012 - 2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada.
The market of radiopharmaceuticals is dominated by diagnostic radioisotopes, comprising of SPECT and PET radioisotopes. The lions share of the SPECT market is taken up by Tc-99m, whereas the PET market is dominated by F-18FDG isotope.
Big Market Research : World Anti-Inflammatory Therapeutics Market - Size, Share, Trends, Demand, Report, Opportunities and Forecast 2020 To Get More Details @ http://www.bigmarketresearch.com/anti-inflammatory-therapeutic-market Inflammation is triggered by the defense system of the body in response to harmful stimuli, damaged cells, irritants and microorganisms. Inflammation is the mechanism of innate immunity, which seeks to eliminate the cause of injury, clear dead and necrotic cells and heal injured tissues. Sometimes, the body defense system inappropriately triggers inflammation against its own cells, resulting in incurable inflammatory autoimmune diseases such as arthritis, asthma and chronic obstructive pulmonary disease (COPD). According to World Health Organization (WHO), approximately 235 million people suffer from asthma in the world.
Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. See Full Report @ bit.ly/12yBegp
Global lower respiratory tract therapeutics market size is expected to reach $48.37 Bn by 2028 at a rate of 7.8%, segmented as by disease type, asthma, chronic obstructive pulmonary disease, pneumonia, tuberculosis, bronchitis, other diseases
The human respiratory system plays a vital role in our well-being, allowing us to take in oxygen and expel carbon dioxide. The global Respiratory Market Size reached a substantial USD 142.3 billion in 2023, and is projected to witness a robust CAGR of 5.8%, exceeding an estimated value of USD 213.4 billion by 2030.
The report "Digital Therapeutics Market by Application (Prevention (Prediabetes, Obesity), Care (Diabetes, CVD, CNS, CRD, Smoking Cessation, Musculoskeletal)), Sales Channel (B2C (Patient, Caregiver), B2B (Provider, Payer, Employer, Pharma)) - Global Forecast to 2021", The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021.
Global nasal drug delivery technology market size is expected to reach $110.08 Bn by 2028 at a rate of 7.3%, segmented as by dosage form, nasal spray, nasal drops, nasal gels and ointments, nasal powders, other dosage forms
The global respiratory market size reached a staggering USD 42.3 billion in 2023. This impressive figure highlights the significant need for respiratory devices and treatments to address a wide range of respiratory conditions. The market is projected to grow at a Compound Annual Growth Rate (CAGR) of approximately 7.4%, reaching an estimated USD 64.2 billion by 2030.
The human respiratory system, responsible for our very breath, is vital for life. When respiratory illnesses strike, the need for effective solutions becomes paramount. This blog delves into the respiratory market in 2024, exploring its size, segmentation, key trends, and future outlook.
Big Market Research adds a report “Asthma Therapeutics Industry- Size, Share, Trends, Forecast, Growth, Opportunities, Outlook " Get Complete Report @ http://www.bigmarketresearch.com/global-asthma-therapeutics-industry-2015-research-report-market 2015 Global Asthma Therapeutics Industry Report is a professional and in-depth research report on the worlds major regional market conditions of the Asthma Therapeutics industry, focusing on the main regions (North America, Europe and Asia) and the main countries (United States, Germany, Japan and China). Enquire about this report @ http://www.bigmarketresearch.com/report-enquiry/367423
Research Beam added report on "Global Asthma Therapeutics Industry Development, Size, Share, Trends, Segmentation, Growth, Technology, Opportunity, Analysis and Forecast 2015" Enquiry about report: http://www.researchbeam.com/global-asthma-therapeutics-industry-2015-deep-research-report-market/enquire-about-report
Inflammation is triggered by the defense system of the body in response to harmful stimuli, damaged cells, irritants and microorganisms. Inflammation is the mechanism of innate immunity, which seeks to eliminate the cause of injury, clear dead and necrotic cells and heal injured tissues. Sometimes, the body defense system inappropriately triggers inflammation against its own cells, resulting in incurable inflammatory autoimmune diseases such as arthritis, asthma and chronic obstructive pulmonary disease (COPD).
According to our new market research study on “Allergy Immunotherapies Market to 2027 – Global Analysis and Forecast – by Application and Distribution Channel,” the market is expected to reach US$ 4,185.89 million by 2027 from US$ 1,819.18 million in 2019. The market is estimated to grow with a CAGR of 11.1% from 2020 to 2027. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth.
Download sample brochure @ http://tinyurl.com/jeu5bak This report provides comprehensive information on the therapeutic development for Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Asthma and special features on late-stage and discontinued projects.
The global mass spectrometry market size reached USD 4.36 Billion in 2021 and is expected to register a revenue CAGR of 6.1% during the forecast period, according to latest analysis by Emergen Research. Increased spending by pharmaceutical companies on research & development activities is a major factor driving market revenue growth. These research activities are also facilitating developments and drawing in investments in biopharmaceutical and personalized medicine.
Pulmonary Devices Market was valued at US$ 18,598.56 million in 2019 and is projected to reach US$ 39,965.01 million by 2027; it is expected to grow at a CAGR of 10.1%from 2020 to 2027. Get PDF Sample Copy @ https://bit.ly/3rh68He
A leading business intelligence provider, has released its latest research report, “Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options”, which provides in-depth insight into the indication. It provides estimates of market size for 2013 along with forecasts until 2020 for the eight major developed markets, which comprises the US, UK, France, Germany, Italy, Spain, Japan and Canada. See Full Report @ bit.ly/1wvLvR8
According to a new market research study titled ‘Digital Therapeutics Market to 2025 – Global Analysis and Forecasts by Application and Distribution Channel, the global digital therapeutics market was valued at US$ 1,993.2 Mn in 2017 and is estimated to reach US$ 8,941.1 Mn by 2025. The market is estimated to grow with a CAGR of 20.8% from 2018-2025. The report highlights the trends prevalent in the global digital therapeutics market and the factors driving the market along with those that act as deterrents to its growth. Download Sample Copy at http://bit.ly/2OmqZbn
According to Renub Research analysis Respiratory Care Devices Market will be US$ 30.5 Billion by 2025. Global Analysis & Forecast by Product (2020 - 2025). Access full Research: https://www.renub.com/respiratory-care-devices-market-p.php
Some of the players identified in the Home Respiratory Therapy Market include: Genesis Rehab Services West River Health Services Fisher & Paykel Healthcare Limited Medtronic plc Dräger Safety AG & Co. KGaA
The global respiratory devices and equipment (therapeutic and diagnostic) market size is expected to grow from $25.23 billion in 2021 to $28.97 billion in 2022 at a compound annual growth rate (CAGR) of 14.8%.
Internet of Things (IoT) Healthcare Market is Expected to Reach $136.8 Billion, Worldwide, by 2021. To read more at: https://www.alliedmarketresearch.com/iot-healthcare-market According to a new report published by Allied Market Research titled, "World Internet of Things (IoT) Healthcare Market - Opportunities and Forecasts, 2014-2021" , the world internet of things (IoT) healthcare market is expected to reach $136.8 billion by 2021, registering a CAGR of 12.5% between 2015 and 2021. Services and system & software segments collectively occupies a dominant share in the world IoT healthcare market and is expected to drive the growth over the forecast period. Patient monitoring application segment is expected to maintain its lead position with $72.7 billion by 2021.
Get a detailed report at http://www.marketoptimizer.org/cvt-301-parkinsons-disease-forecast-and-market-analysis-to-2022.html . CVT-301 has been developed by Civitas Therapeutics as the company’s leading candidate for the treatment of OFF episodes in Parkinson’s disease. Using the ARCUS inhaler platform, levodopa is inhaled into the lung where it is delivered to the blood, avoiding the gastrointestinal tract and producing more rapid effects than orally administered levodopa. CVT-301 will be taken as needed, similar to a “rescue inhaler,” which is common in the asthma market. It will not replace the patient’s current oral doses of levodopa or other medications, but will be taken in addition to them.
The Business Research Company offers respiratory devices and equipment (therapeutic and diagnostic) market research report 2023 with industry size, share, segments and market growth https://bit.ly/3mwbj4S
Global Market Estimates is a market research and business consulting company who has proven track record in serving Fortune 500 companies. Request for a sample copy of the ‘Spirometry Market’report @: https://www.globalmarketestimates.com/global-spirometry-market-analysis/
Major players in the biosimilar interleukins market are MabPharm, Gedeon Richter, Bio-Thera Solutions, Sorrento Therapeutics/MabTech, and Sunshine Guojian Pharmaceutical..... @ @ https://bit.ly/3qztA1o
Global immunomodulators market is rising gradually with a substantial CAGR of 5.8% in the forecast period of 2019-2026. Raising investment in the R&D and technological advancement will also uplift the growth of this market.
Global Prescription digital therapeutics (DTx) market is rising gradually with a healthy CAGR of 23.35% in the forecast period of 2019-2026. Growing prevalence of cancer worldwide and expanding the application of CRISPR technology by innovative research from the different academic organizations are the key factors for market growth.
Cytokine release syndrome is defined as a type of condition which is caused when rapid release of cytokines occurs from the immune cells into the bloodstream. Cytokine release syndrome occurs after the treatment of immunotherapies such as monoclonal antibodies and CAR-T cells. People may experience high fever, nausea, headache, hypotension, rash, rapid heartbeat, low blood pressure and difficulty in breathing.
Global Pulmonary Function Testing Market expected to rise from its initial estimated value of USD 367.88 million in 2018 to an estimated value of USD 691.07 million by 2026 registering a CAGR of 8.2% in the forecast period of 2018-2026. This rise in the market can be attributed to the increasing prevalence of lung cancer, rapidly increasing geriatric population, obesity and increasing healthcare expenditure.
According to MRFR Analysis – silent heart market is growing at a CAGR of 5.7% during the forecast period 2017 to 2023. The global market industry categorizes by type, indication, devices, end user, and region.
Big Market Research “Asthma Drugs Market in the US” Size, Share, Industry Trends, Demand, Insights, Analysis, Research, Report, Opportunities, Company Profiles, Forecast to 2019. Visit for more info @ http://www.bigmarketresearch.com/asthma-drugs-in-the-us-2015-2019-market Asthma is a disease that affects the lungs and is characterized by wheezing, coughing, breathlessness, and chest tightness. It is a chronic ailment of the respiratory tract, which is caused by the obstruction of the flow of air and bronchospasms, where the muscles around the respiratory tract swell up. The disease is believed to be caused by genetic as well as environmental factors.
GBI Research, the leading business intelligence provider, has released its latest research, Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 Increasing Uptake of Novel Drug Classes to Drive Market Growth, which provides insights into type 2 diabetes in the Asia-Pacific (APAC) markets of China, India, Japan and Australia. The report estimates the market size for 2013 and provides a forecast until 2020, and covers disease epidemiology, treatment algorithms, and treatment use patterns. It also provides in-depth analysis of the pipeline molecules, clinical trial failure rates, and recent deals. The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research’s team of industry experts. View full report with TOC: http://www.reportsandintelligence.com/digest-aesthetic-lasers-and-energy-devices-2006-to-2020-asia-pacific-market
Lung Cancer Diagnostics Market size should witness significant growth due to increased prevalence of smoking and exposure to secondhand smoke, influencing the occurrence rate of lung malignancies. Smoking is forestalled to be the major cause of approximately 85 per cent of cancer. The surging dominance of cancer is directly proportional to the business growth, owing to the high demand for diagnosis and early disease screening. Mounting technological advancements such as the development of specific biomarkers facilitates the customized treatment approach of lung malignancies eventually driving the lung cancer diagnostics market during the forecast period. The rising awareness levels amongst the populace and the availability of government as well as private funds for R&D of better tumor diagnostic tools further fuels the industry growth.